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Abstract
BTN3A2/BT3.2 butyrophilin mRNA expression by tumoral cells was previously identified as a prognostic factor in a small
cohort of high grade serous epithelial ovarian cancer (HG-EOC). Here, we evaluated the prognostic value of BT3.2 at the
protein level in specimen from 199 HG-EOC patients. As the only known role of butyrophilin proteins is in immune
regulation, we evaluated the association between BT3.2 expression and intratumoral infiltration of immune cells by
immunohistochemistry with specific antibodies against BT3.2, CD3, CD4, CD8, CD20, CD68 and CD206. Epithelial BT3.2
expression was significantly associated with longer overall survival and lower risk of disease progression (HR=0.651,
p=0.006 and HR=0.642, p=0.002, respectively) and significantly associated with a higher density of infiltrating T cells,
particularly CD4+ cells (0.272, p,0.001). We also observed a strong association between the relative density of CD206+ cells,
as evaluated by the ratio of intratumoral CD206+/CD68+ expression, and risk of disease progression (HR=1.355 p=0.044,
respectively). In conclusion, BT3.2 protein is a potential prognostic biomarker for the identification of HG-EOC patients with
better outcome. In contrast, high CD206+/CD68+ expression is associated with high risk of disease progression. While the
role of BT3.2 is still unknown, our result suggest that BT3.2 expression by epithelial cells may modulates the intratumoral
infiltration of immune cells.
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Introduction
Epithelial ovarian cancer (EOC) is a leading cause of death
among gynecologic malignancies [1]. Due to its lack of symptoms,
this disease is often diagnosed at an advanced stage (stage III or
IV) when the cancer has already spread to secondary sites. The
standard treatment for these patients is surgery and platinum-
based chemotherapy, although the disease often progresses even
after surgery and becomes resistant to standard chemotherapy [2].
Consequently, the survival rate of patients with advanced-stage
EOC is extremely low (,40%). Clinical variables, such as disease
stage and residual disease, are prognostic [3,4], but largely
uninformative for those with advanced-stage disease.
In a previous study [5], we performed a mRNA expression
profiling of high grade serous EOC tumor tissues to identify
molecular markers of prognosis using an Affymetrix-based gene
expression microarray platform. Among the prognostic markers
identified, we found BTN3A2, also known as BT3.2 and BTF4, a
gene belonging to the BT3 butyrophilin family, also a B7
subfamily. BTN3A2 mRNA was the most robust biomarker
among 8 others tested. Not only did it have a prognostic
significance in univariate and multivariate analyses, but it also
showed the highest hazard ratio compared with the other
molecular and clinical prognostic variables. High mRNA expres-
sion of BT3.2 was strongly associated with a good prognosis in
relation to disease-free survival and overall survival. As an EOC
prognostic marker it reached 87% specificity and 77% sensitivity
to predict early recurrence (,18 months) in a cohort of 52 patients
[5].
The butyrophilin (BTN) family contains BTN1A1, BTN2A1,
BTN2A2, BTN2A3, BTN3A1, BTN3A2, BTN3A3, and BTN-
Like members. Interestingly, these novel BTN family members
share considerable homology with B7 family members, which have
an IgV-like exoplasmic domain followed by another exoplasmic
IgC-like domain. The cytoplasmic domain contains a protein
binding SPRY/PRY B30.2 domain [6,7,8]. Unlike other BTN
members, BT3.2 does not have a B30.2 domain in the intracellular
region [7,9]. BT3 molecules (BTN3A1/BT3.1, BTN3A2/BT3.2
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cells [10], in the membrane layer surrounding milk fat-secreting
droplet from mammary epithelial cells [11], on immune cells, and
on some tumor cell lines [5,12].
The B7 molecules can be negative or positive regulators of T
cell activation. B7-H1/PD-L1, B7-H3, B7-H4, B7DC/PD-L2,
B7S3, B7S1, BTNL2, BTN1A1, BTN2A2 can inhibit T cell
proliferation delivering an inhibitory signal. Conversely, B7-H3
has been regarded as a positive and negative regulatory molecule
able to stimulate or inhibit CD4+ and CD8+ T cells depending of
the cellular context [13,14,15,16]. Similarly, some BTN family
members have recently emerged as new regulators of the immune
system. These include BTNL2 [17–18] BT1.1, BT2.2 [19],
BTNL1 [20,21] and the BT3 molecules. For example, Yamashiro
et al. [22] treated PMBC with an antibody against BT3.3 and
observed an inhibition of CD4+ and CD8+ cell proliferation, as
well as decreased cytokine secretion by both types of T cells. In
another report, Cubillos-Ruiz et al. showed that BT3 expression on
antigen-presenting cells (APC) inhibited in vitro T cell proliferation
and Th1 cytokine secretion [23]. While these studies have looked
at the function of B7 family members when expressed on the
immune component, it is not clear how these molecules might
affect immune response when expressed by other cell types.
Indeed, published data supports the expression of BT3 on EOC
cells in primary tissues and metastatic tissues [23]. In addition,
Messal N. et al. recently reported that BT3 acts as a co-stimulatory
molecule on CD4+ T cells and NK cells [24]. Interestingly, they
observed a differential immuno-regulatory role of the different
BT3 isoforms. Altogether this suggests that complex mechanisms
may govern the function of the BT3 molecules. Further
observations are needed to understand the exact role of these
molecules in a context specific manner.
To better understand the role of BT3.2 in ovarian cancer and
more particularly to confirm our observed association of mRNA
BT3.2 expression with a good patient prognosis [5], we performed
an immunohistochemistry analysis of BT3.2 protein expression on
a large cohort of 199 high grade serous EOC patients and
confirmed the association of BT3.2 and prognosis of EOC
patients. In parallel, we analyzed the density of intratumoral
immune cells and found a positive correlation between BT3.2
expression by EOC cells and intratumoral infiltration of T cells,
whilst a high CD206+/CD68+ expression ratio was associated to
shorter disease-free survival. These results suggest a role of BT3.2
in the tumor infiltration of immune cells.
Materials and Methods
Ethics Statement
Ethics approval was obtained by the local institutional ethics
board (comite ´ d’e ´thique de la recherche du Centre hospitalier de
l’Universite ´ de Montre ´al). Tumor samples were collected and
banked following appropriate written consent from patients
undergoing surgery within the Oncology Department at the
Centre Hospitalier de l’Universite ´ de Montre ´al from 1993 to 2010.
Patients and Tissue Specimens
Tumor samples were collected and banked following appropri-
ate consent from patients undergoing surgery within the Division
of Gynecologic Oncology at the Centre Hospitalier de l’Universite ´
de Montre ´al from 1993 to 2010. An independent pathologist
scored tumor grade and stage and a gynecologic oncologist scored
tumor residual disease according to criteria from the International
Federation of Gynecologists and Obstetricians [25]. Less than
10% of specimen were excluded on quality, and this was not
correlated to age of sample. Clinical data on progression-free
interval were defined according to scan imaging and level of blood
CA125 [26]. Overall survival was defined as the time from surgery
to death from ovarian cancer. Patients known to be still alive at
time of analysis were censored at time of their last follow-up.
Patient disease free survival (DFS) was calculated from the time of
surgery until the first progression. Eligibility criteria for inclusion
in the study were as follows: no pre-operative chemotherapeutic
treatment for ovarian cancer, platinum-based post-operative
chemotherapy treatment, high grade tumors, serous histopatholgy
subtype and completed informed consent. All patients received a
platinum-based chemotherapy as an initial therapy after surgery
with the exeption of patients who died shortly (,3 months) after
surgery. Patients who died from another disease were censored at
time of last follow-up. A gynecologic oncologist reviewed the
clinical data for all patients. For the disease-free progression study,
only patients with clinical follow-up of at least 18 months or until
disease recurrence were included. The characteristics of the
tumors and patient outcome for the sample sets are summarized in
Table 1.
Cell Cultures and Cell Pellets in Histogel
To verify the specifity of the BT3.2 antibodies, TOV-112D cells
and derived cell lines were cultured in OSE medium (50:50 mix of
199 and 105 Sigma mediums) supplemented with 0.5 mg/mL of
amphotericin B, 50 mg/mL of gentamycin and 10% of FBS (fetal
bovine serum). Derived cells media were also supplemented with
0.5 mg/mL of puromycin. Cells were maintained in an incubator
humidified at 37uC with an atmosphere containing 5% of CO2
essentially as described [27]. Cells pellet embedded in paraffin
were prepared as previously described [28].
Plasmids
The BT3.1, BT3.2 and BT3.3 sequences were subcloned in the
pef6v5 vectors and were a generous gift of Dr Rhodes (Cambridge,
UK) [7]. All plasmids were verified by sequencing. The BT3
isoform sequences were PCR amplified and subcloned in the
pENTR
TM/D-TOPOH (Invitrogen, Carlsbad,  CA) and then re-
combined in the pLenti-CMV/TO-puoDest (Abgene) [29].
Lentiviral particles production and cell infection was done as
previously reported [30].
Tissue Microarray
Areas of tumor were selected based on review of a hematoxylin-
eosin-stained slide. FFPE tumor blocks were then biopsied using a
0.6 mm diameter tissue arrayer and resultant cores were arrayed
into a grid in a recipient paraffin block. The tissue array was
composed of 260 ovarian cancer samples and 11 samples of areas
from normal fallopian tubes of cancer patients. After review of
clinical data 61 patients were excluded from the final analysis as
they did not meet the inclusion criteria. This tissue array was then
sectioned, stained with hematoxylin-eosin and received another
pathology review to confirm tumor content.
Immunohistochemistry (IHC)
Formalin fixed paraffin embedded tumors were sectioned at
4 mm and the slides were stained manualy on the bench or using
the BenchMark XT automated stainer (Ventana Medical System
Inc.). For the manual method, tissue sections were heated briefly at
50uC for 15 minutes, deparaffinized in toluene and rehydrated in
an ethanol gradient. Slides were submerged in Tris-EDTA buffer
(10 mM Tris base, 1 mM EDTA adjusted to pH 9.0) and pressure
cooked for 15 min to unmask antigens. A 0.6 or 3% H2O2
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The sections were blocked with a protein blocking serum-free
reagent (DakoCytomation Inc., ON, Canada) and incubated with
different antibodies for 60 or 120 min at room temperature. The
optimal concentration for each primary antibody was determined
by serial dilutions. Antibodies and IHC conditions are listed in
Table S1. Tissues were incubated with a goat anti-mouse HRP-
conjugated antibody (1:150) (sc-2005, Santa Cruz Biotechnology,
CA, USA). For BT3.2, tissues were incubated with a secondary
biotinylated antibody (DakoCytomation Inc., ON, Canada) for
30 min followed by incubation with a streptavidin-peroxidase
complex (DakoCytomation Inc., On, Canada) for 30 min at room
temperature. Reaction products were developed using diamino-
benzidine containing 0.3% H2O2 as a peroxidase substrate. Nuclei
were counterstained with hematoxylin. With the automated
stainer, antigen retrieval for CD206 and CD4 was carried out
with Cell Conditioning 2 (VMSI; #950–123). Prediluted antibody
was automatically dispensed, and the slides were incubated at
37uC for 30 min. UltraView DAB detection kit (VMSI; #760–
091). Slides were counterstained with hematoxylin (VMSI; #760–
2021). All sections were observed by light microscopy at 4006
magnification. Substitution of the primary antibody with phos-
phate buffered saline served as a negative control.
Immunofluxorescence (IF)
Formalin fixed paraffin embedded tumors were stained
manualy after antigen retrieval in Tris-EDTA (10 mM Tris base,
1mM EDA adjusted to pH 9.0) for 15 min in pressur cooker. The
sections were blocked with a protein blocking serum-free reagent
(DakoCytomation Inc., ON, Canada) and incubated with the anti-
CD68 antibodies for 90 min at room temperature. Tissues were
then incubated with a goat anti-mouse Cy5 (1/200) for 45 min.
Mouse IgG antibodies were then blocked overnight with
M.O.M.
TMreagent (Vector Laboratories, Burlingame, CA). Anti-
CD206 antibodies were incubated for 90 min at room tempera-
ture. Tissues were then incubated with goat anti-mouse Alexa
Fluor A488 (1/250) for 45 minutes before washing and treatment
with 0.1% Sudan black B for 10 min to reduce autofluorescence.
Slides were counterstained with ProLongH gold antifade fluores-
cent mounting media with DAPI (Molecular Probes). The reading
was performed by microscope analysis at high power and then
dual immunoflourescent staining was evaluated for validation.
Staining Quantification
Tumor sections were scanned and digitally visualized. For
BT3.2, epithelial zones were scored according to the staining
intensity of the epithelial membrane (value of 0 for absence, 1 for
weak, 2 for moderate, 3 for high intensity) as illustrated in Figure 1.
In cores where staining was of variable intensity the average
intensity was reported. The quantification of infiltrating lympho-
cytes was carried out by counting the number of nucleated cells
with positive staining in intraepithelial islets. Results were then
categorized as 0 (no cells), 1 (0,n,10), 2 (10,n,90) and 3
(n.90) accordingly of the number of cells counted. The
quantification of macrophages was carried out by evaluating the
percentage of stained cells in the intraepithelial area. The relative
density of CD206+cells was calculated by the ratio CD206+/
CD68+ stained cells. Each array was independently analyzed in a
blind study by two independent observers. Inter-rating correlation
was .75%. When strong differences in scoring between the two
Table 1. Clinical characteristics of the patients included in the cohort.
Characteristics Number of patients Time (range)
AGE 199 61 yr (34–89 yr)
STAGE I1 0
II 20
III 140
IV 27
RES.DISEASE neg 23
.1c m 2 6
1–2 cm 15
2c m 6 1
milliary 15
SURVIVAL TIME Incidence of death 74 26 mo (1–74 mo)
FOLLOW UP TIME 118 40 mo (1–140 mo)
DIS. PROGRESSION TIME ,18 mo 82 9 mo (1–17 mo)
.20 mo 93 50 mo (20–140 mo)
BT3.2 staining ,13 5
1–2 121
.24 2
missing 1
Stage was divided in 4 categories according to FIGO classification. The histological grade of the tumor was evaluated by a pathologist and divided in two groups (grade
2 or 3) according to the FIGO grading system. Residual disease at surgery (Res. Disease) was evaluated in centimeter (cm) by a gyneco-oncologist. Neg= no residual
disease. Survival and follow up time is the time in months (mo) from the date of primary resection of the ovarian tumor until the event of death due to ovarian cancer or
until the last contact with the patient. Disease progression time is the time of disease progression from the date of primary resection of the ovarian tumor until the first
event of disease progression. BT3.2 staining is the staining intensity observed on the tissue microarray analysis with an antibody against BT3.2. Intensity 1: weak.
Intensity 2: moderate. Intensity 3: strong. For additional details see Materials and Method section.
doi:10.1371/journal.pone.0038541.t001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e38541Figure 1. BT3.2 expression in ovarian cancer cells. A. Western-blot analysis of total protein extracts from TOV112D cell line infected with PLenti
(vector control), BT3.1, BT3.2 or BT3.3 viral constructs. Extracts were loaded in triplicate on 10% SDS/PAGE gel and membranes were hybridized with
anti-CD277 (eBioscience), anti-BT3.3 (Atlas Antibodies) and anti-BT3.2 (SDIX Inc.) as indicated at the bottom of the Figure. B. Immunohistochemistry
analysis of paraffin-embedded cell pellets from TOV112D cell line infected with either PLenti (vector control), BT3.1, BT3.2 or the BT3.3 viral constructs.
Only cells transfected with the BT3.2 construct stained positively with the anti-BT3.2 (SDIX Inc.). C. Immunohistochemistry of xenograft tumors from
TOV112D transfected with either empty vector or BT3.2 construct. Only cells infected with the BT3.2 construct stained positively with the anti-BT3.2
(SDIX Inc.). D. Representative staining for immunohistochemistry of BT3.2 on a high-grade serous EOC TMA. From left to right: negative, low,
moderate and high intensity.
doi:10.1371/journal.pone.0038541.g001
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evaluated to reach a concordant scoring between the two
observers. The average of all cores with cancer from the same
patient was used for analysis.
Western Blot Analysis
Cells were lysed with cold lysis buffer (10 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT/1 mM NaF/
0.5% NP-40/and protein inhibitors) and centrifuged for 10 min at
13000 rpm. Clear lysates were then boiled in loading buffer,
separated by 10% SDS-PAGE, and transferred on a nitrocellulose
membrane. Membranes were saturated with 5% milk/PBS/0.1%
Tween 20. Immunodetection was done as described in the
protocol of the ECL kit (Amersham Pharmacia): i.e. incubated 2 h
at room temperature or O/N at 4uC with the specific antibody,
washed with PBS/Tween 0.01% and incubated for another
30 min at room temperature with peroxidase conjugated antibod-
ies (Santa-Cruz Biotechnology Inc.). Western-blot analysis was
performed with beta-actin AC-15 (ab6276 from Abcam inc. MA,
USA), anti-CD277/BT3.1 (#14–2779 from eBioscience, San
Diego, CA, USA), anti-BT3.2 (SDIX, Newark DE, USA), anti-
BT3.3 (HPA007904, Atlas Antibodies, Stockholm, Sweden).
Experiments were done in triplicate.
Statistical Analysis
The Pearson correlation test (two-tailed) was used to estimate
the correlation with clinico-pathological variables and markers as
continuous variables. Survival curves were plotted using the
Kaplan-Meier curve analysis and the log-rank test was used to test
for significant differences. Receiver operative characteristic (ROC)
curves were used to determine the threshold value for each marker
corresponding to the best sensitivity and specificity for patient
progression before 18 months (early disease progression) or after
20 months (late disease progression) from initial diagnosis (p,0.05
and area.0.60) as already reported [5]. Univariate and multivar-
iate Cox proportional hazard models were used to estimate the
hazard ratio for each marker as continuous variables. Multivariate
analysis was done using a forward stepwise hazard model on
univariate analysis required for entry into the model. Only four
variables were including in the multivariate Cox regression model
to avoid over-fitting. Multivariate analysis was performed using an
enter hazard model. Sample size (n .100 where n=10k/p) and
normal distribution of BT3.2 expression were considered before
applying the Cox model. All statistical analyses were done using
Statistical Package for the Social Sciences software version 11.0
(SPSS, Inc.), and statistical significance was set at P,0.05.
Results
Expression of BTN3A2/BT3.2 in EOC Tissues
To investigate the association between of BT3.2 expression in
EOC cells and patient survival, we performed an immunohisto-
chemistry analysis in a cohort of 199 high-grade serous ovarian
cancer patients. First, we evaluated the specificity of available
antibodies against BT3 isoforms. We found 3 different antibodies
commercially available: anti-CD277 (eBioscience Inc.), anti-BT3.3
(Atlas) and anti-BT3.2 (from SDIX Inc.). Antibodies were tested
by western-blotting on cellular extracts from the TOV112D
ovarian cancer cell line infected with either BT3.1, or BT3.2 or
BT3.3 retroviral particles. As seen in Figure 1A, the anti-CD277
recognized BT3.1 and BT3.2 isoforms. As expected, the anti-
BT3.3 antibody exclusively recognized the BT3.3 isoform and the
anti-BT3.2 specifically recognized the BT3.2 isoform. To confirm
the specificity of the anti-BT3.2 antibody on paraffin embedded
tissues, we also analyzed the staining of paraffin-embedded cell
pellets and xenograft tissues from 112D TOV cells transfected
with either an empty vector or BT3 isoform constructs. As seen in
Figure 1B and 1C, the anti-BT3.2 antibody was able to stain only
the BT3.2 cell pellet and BT3.2 xenograft tumor.
Membrane and cytoplasmic expression of BT3.2 in ovarian
cancer tissues was observed and scored according to the intensity
of staining as absent, low, moderate or strong (0, 1, 2, 3
respectively) (Figure 1D). Presence of BT3.2 protein was observed
on epithelial cells and in some tissue cores, it could also be found in
the stroma. Almost all EOC cores (n=193, 97.5%) showed
expression of BT3.2. On epithelial cells, both cytoplasmic and
membrane staining were seen (Figure 1D) and varied from absent
to strong (Figure 1D, Table 1). The epithelial BT3.2 expression
levels did not significantly correlated with patient age at diagnosis
or tumor grade. In contrast, patients with higher level of epithelial
BT3.2 tend to have lower level of residual disease and lower stage
disease (p=0.058 and p=0.043, respectively, Table 2).
BT3.2 Protein Expression is Associated with Overall
Survival and Disease-free Progression
We have previously investigated the relation between BT3.2
mRNA expression and ovarian cancer patient prognosis. Kaplan-
Meier and Cox proportional hazard model were used to estimate
the association between BT3.2 mRNA and prognosis as defined by
overall survival or disease-free survival (DFS) within 18 months
after surgery [5]. In the present study, we investigated whether
BT3.2 protein could also be of prognostic value. For this purpose,
protein expression of BT3.2 was analyzed in 199 high-grade
serous patients and statistical analyses were performed with respect
to overall survival and DFS. The cohort characteristics are
described in Table 1.
Kaplan-Meier curves showed that there was a strong association
between high expression of BT3.2 protein and increased overall
patient survival (p=0.014; log rank=6.03) (Figure 2A). Mean
survival interval was 85 months for patients with higher level of
BT3.2 compared with 59 months for patients with low level of
BT3.2. Similarly, patients with higher expression of BT3.2 had a
mean progression interval of 86 months compared to 55 months
for patients with low expression of BT3.2 (p=0.002, log
rank=9.65) (Figure 2B).
In univariate Cox regression analysis, the continuous level of
BT3.2 protein was evaluated to reflect the relation between
increasing level of BT3.2 expression and improved prognosis. In
this analysis, increased expression of BT3.2 was associated with a
relatively high hazard risk (HR) for survival (HR=0.651, 95%CI
0.479–0.884, p=0.006, Table 3). Similarly, increased BT3.2
expression was significantly associated with later disease progres-
sion (HR=0.642, %95CI 0.483–0.853, p=0.002) (Table 3).
In multivariate Cox regression analysis, when standard prog-
nostic variables were undertaken (age, stage and residual disease),
BT3.2 remained an independent variable predicting a high risk of
survival (HR=0.597, %95CI 0.415–0.859, p=0.005) and late
progression risk in this multivariate model (HR=0.675, %95CI
0.487–0.935, p=0.018) (Table 3).
Relationship Between BT3.2 Expression and Immune
Infiltrate
We hypothesized that the relation between epithelial BT3.2
expression and a good prognosis was due to the influence on
tumor infiltrating immune cells, since it is known that B7 family
molecules have co-regulatory functions on T cells. In addition, the
level of intratumoral immune cell infiltration has been related to
Butyrophilin and Outcome of Ovarian Cancer
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38541prognosis of ovarian cancer patients [31]. To investigate this
hypothesis, we evaluated by immunohistochemistry the presence
of T cells by CD3+, CD4+ and CD8+ staining in the same TMA
used for BT3.2 analysis. We also assessed the importance of
intratumoral B cell (CD20+) and macrophage (CD68+) infiltra-
tion. Two classes of macrophages have been described, anti-
tumoral (M1) and pro-tumoral (M2). Since in most tumors, tumor-
associated macrophages (TAM) have an M2-phenotype [32,33],
we determined the density of infiltrating CD206+ cells as a
surrogate marker of alternative pro-tumoral M2 macrophages
since they tend to express higher level of CD206 marker than M1
macrophages. To confirm the specificity of CD206 expression by
macrophages in EOC tumors, we performed a control double
immunofluorescent staining on a limited number of tissues (Figure
S1). CD206 expression almost always co-localized with CD68
expression suggesting macrophage expression.
As seen in Figure 3 and Figure 4A-B, immune infiltration of T
cells, B cells and TAM was observed in EOC tissues at various
densities in the intraepithelial areas. The intraepithelial infiltration
of T cells, CD3+, CD4+ or CD8+, was highly correlated with the
presence of CD20+ B cells (p,0.001) and CD68+ macrophages
(P,0.001), including the CD206+ cells (Table 4). The intraepi-
thelial infiltration of B cells was also associated with the presence of
CD68+ and CD206+ cells (r=0.364 and r=0.171, p,0.001 and
p=0.022, respectively). Interestingly, the proportion of CD206+
cells relative to the total density of CD68+ macrophages, the ratio
CD206+/CD68+ expression, was inversely correlated to the
presence of CD3+T cells and tended to correlate with the
presence of B cells (r=-0.216, p=0.005 and r=-0.141, p=0.063,
respectively) (Table 4).
Significantly, the expression of BT3.2 by EOC cells was
correlated with the intraepithelial infiltration of CD3+ cells
(r=0.174, p=0.018), including CD8+ cells (r=0.176, p=0.018)
and CD4+ cells (r=0.272, p,0.001). No significant correlation
between BT3.2 expression and the presence of CD20+ cells or
macrophages was seen (p=0.137, Table 4).
Association of Intratumoral Lymphocytes, Macrophages
and EOC Patient Prognosis
As reported by others [31], the presence of CD4+ cells was also
inversely correlated with early disease progression (r=-0.187,
p=0.021, Table 5). Kaplan-Meier curve analysis and log rank test
confirmed that high intraepithelial density of CD4+ was associated
with a better prognosis (Table S2). The mean progression interval
of patients with high intra-epithelial CD4+ cells was 69 months, as
compared to 59 months for patients with low intraepithelial CD4+
Table 2. Pearson correlation test (two-tailed) between BT3.2 expression in EOC tissues and clinical parameters of patients.
AGE GRADE STAGE CA125 Res. Disease Recurrence DEATH
BT3.2 Correlation 20.017 0.082 20.145 0.071 20.16 20.218 20.23
p 0.812 0.249 0.043 0.391 0.058 0.004 0.001
N 194 198 196 149 140 174 198
Table showing the coefficient of correlation with a Pearson correlation test (Correlation) between clinical parameters and BT3.2 staining intensity observed in the intra-
epithelial area of ovarian tumor tissues. Grade and stage were evaluated according to the FIGO classification as described in Materials and Methods. Res. Disease is the
amount of residual disease at primary resection of the tumor as classified in Table 1. Recurrence is the first event of ovarian cancer recurrence after the primary resection
of the tumor. CA125= blood serum level CA125 at the date of primary resection of the ovarian tumor. P is the p value from Pearson correlation test. N is the number of
cases included in the statistical analysis.
doi:10.1371/journal.pone.0038541.t002
Figure 2. Kaplan Meier analysis of BT3.2 in high-grade serous EOC. Kaplan-Meier curves of overall survival (A) and disease-free survival (B) in
194 and 171 patients, respectively. Significance (p) is indicated by log rank.
doi:10.1371/journal.pone.0038541.g002
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any significant association between intraepithelial density of CD3+
or CD8+ cells and patient prognosis (Table 5 and Table S2). We
found a significant association between CD20+ cell infiltration and
overall survival (log rank p=0.039), whereas only a trend toward a
better disease-free survival was obtained (log Rank p=0.0677).
However, the association with overall survival was not seen when
CD20+ was considered as a continuous variable in univariate Cox
regression model (p=0.21).
Whilst we did not observe a correlation between the density of
CD68+ or CD206+ cells and patient prognosis (Table 5), an
increased ratio of CD206+ relative to CD68+ cells was positively
correlated with disease progression (r=0.157, p=0.049, Table 5).
This relation was confirmed by Kaplan-Meier curve analysis
(p=0.005, log rank=7.83, Figure 4D, Table S2) and univariate
Cox regression analysis (HR=1.355, 95%CI 1.223–5.332,
p=0.044). Furthermore, the CD206+ relative density tended to
associate with poor overall survival (log rank=3.53, p=0.06)
(Figure 4C, Table S2) with a hazard ratio of 2.077 (%CI 95,
0.947–4.558, p=0.068).
Discussion
In this study, immunohistochemistry revealed BTN3A2/BT3.2
staining in high-grade EOC serous tumors from 199 patients.
Expression was detected at high frequency (97.5%) in accordance
with previous data analyzing the mRNA expression in serous
EOC tissues [5]. The important aspect of this study is the
confirmation of BT3.2 as a potential prognostic marker for high-
grade serous EOC at the protein level. The initial study identifying
BT3.2 mRNA as a prognostic marker was limited to a relatively
small set of 52 cases. Here, not only we confirmed the relation
between BT3.2 and a better outcome in a large cohort, but also at
protein level by immunohistochemistry. This constitutes a more
easily transposable technique in a clinical pathology department
than mRNA detection such as Q-PCR. Patients with high
epithelial staining of BT3.2 had 1.53 times less risk of dying from
the disease than patients with low level of BT3.2 expression. The
association of BT3.2 to survival and to disease progression was an
independent parameter within a multivariate Cox-regression
analysis (Table 3). Combination with other independent molecular
markers could improve its clinical performance as to date no
individual marker has demonstrated sufficient sensitivity and
specificity.
A limitation of our study is the low number of patients with no
residual disease (n=23), which did not allow us to analyze them as
an independent cohort. Optimally debulked patients, overall have
better prognosis than patients with residual disease [34] for which
a prognostic biomarker may be less informative. However, 84% of
the cohort analyzed here had residual disease (Table 1). Notably,
53% of patients showed a disease progression within 18 months
following ovariectomy and 41% died from the disease. Thereby,
even a cohort of patients with residual disease would benefit from
prognostic biomarkers to aid patient management. In addition, the
presence of residual disease is in part due to a surgical limitation
rather than the biological behavior of the tumor, so it is reasonable
to speculate than BT3.2 will also be a significant prognosis marker
in a cohort of optimally debulked patients. This hypothesis still
needs to be validated in such a cohort of EOC patients. Knowing
that immune regulation is an important factor in the outcome of
several epithelial cancers, it is possible than BT3.2 has a similar
role in other carcinomas. In line with this hypothesis we also
observed expression of BT3.2 in breast, renal and colon cancer
tissues (Figure S2). However, the association of this expression and
the outcome of patients for these cancers should be specifically
investigated to confirm this hypothesis.
Ovarian cancers, as do most cancers, involved multimolecular
events, which regulate the mechanisms of cancer progression and
antitumoral response. In the last decade, a number of studies have
shown a major role for immune cells in the host anti-tumor
response to ovarian cancer [31] and tumor-mediated immune
evasion. The first reported observation [35] found that CD3
+ T
cells were associated with better survial and disease-free-progres-
sion in a cohort containing several subtypes of EOC. While some
studies confirmed the relation between intratumoral CD3+T cells
density and EOC patient prognosis [36,37,38], others did not
[39,40] [31,37,41]. Together, these observations suggest that
complex regulatory factors govern tumoral microenvironement
and immune function. To better understand the mechanism and
tumor factors involved in T cell infiltration of ovarian tumors,
several groups have investigated the presence of intratumoral
subtypes of T cells, macrophages (TAM), B cells and immune
regulatory factors [42], levels of cytokines such as TNF or IFNc
[31]. However, mechanisms involved in the immune surveillance
Table 3. Univariate and multivariate Cox regression analysis showing the statistical association between BT3.2 expression and
outcome of EOC patients.
Univariate analysis Multivariate analysis
HR (95%CI) p HR (95%CI) p
OS AGE 0.996 (0.971 1.022) 0.781 0.996 (0.971 1.022) 0.781
STAGE 2.17 (1.399 3.37) 0.001 1.145 (0.645 2.032) 0.643
Res.Dis. 1.654 (1.323 2.068) 0 1.586 (1.233 2.04) 0
BT3.2 0.651 (0.479 0.884) 0.006 0.597 (0.415 0.8590 0.005
DFS AGE 0.998 (0.978 1.018) 0.832 0.997 (0.975 1.019) 0.765
STAGE 1.796 (1.265 2.551) 0 1.353 (0.815 2.2460 0.243
Res.Dis. 1.619 (1.320 1.987) 0 1.527 (1.214 1.922) 0
BT3.2 0.642 90.483 0.853) 0.002 0.675 (0.487 0.935) 0.018
OS= overall survival is the time of survival from the date of primary resection until event of death due to ovarian cancer. Res. Dis.= amount of residual disease at time
of primary resection of the ovarian tumor. Age= age of patient at time of the first resection of the ovarian tumor. DFS= disease free survival is the time from the first
resection of the primary tumor until the first event of recurrence. HR= hazard ratio. CI= confidence interval. P= p value.
doi:10.1371/journal.pone.0038541.t003
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fully understood.
Recently, new members of the B7 family, the butyrophilins,
attracted a strong interest as new T cell regulatory molecules [43].
First, BTNL2 was described as a negative T cell costimulatory
molecule in a murine in vitro assay and in a murine intestinal
inflammation model [17–18]. The murine BT1.1 and BT2.2 were
also identified as co-inhibitors of T cell activation [19]. It is
unknown whether human butyrophilin molecules share similar
immune regulating functions. In human, BT3 is expressed in
various immune cells and tumor cell lines including EOC cells
[23]. A recent study also reported negative co-stimulatory
functions for BT3.3 [22], but not BT3.1, on human blood T cells
using antibodies against the BT3.3 isoform. Conversely, another
study proposed that CD277 (BT3) inhibited human T cells
proliferation when expressed by APC [23]. A last study showed
that CD277 engagment stimulated the activation of human T cells
in vitro [24]. More interestingly, in this study, a differential role of
the BT3 isoforms was reported [24] where BT3.2 was the main
isoform expressed by NK cells and the only one able to inhibit
Figure 3. Representative staining for immunohistochemistry of tumor infiltrating lymphocytes. High and low density of CD3+ (T cells),
CD4+ (T cells), CD8+ (T cells) and CD20+ (B cells) shown in left and middle panels. A magnification in the high infiltration area is shown on the right
panel for each staining.
doi:10.1371/journal.pone.0038541.g003
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that the role of the BT3 isoforms is complex, specific to cell type
and regulated by the combination of isoforms. This also raised the
question whether BT3 isoforms share the same receptor or
whether the 3 isoforms bind to specific receptors, which could
transmit different and perhaps opposite activation signals. In
addition, one could also speculate that CD277 expressed by
myeloid APCs (potentially pro-inflammatory as a ligand) could
have a different role than CD277 expressed by T cells (potentially
anti-inflammatory as a receptor) or by epithelial cells. We do not
know yet if BT3 isoforms expressed by EOC cells have similar
functions than isoforms expressed by immune cells. Further
observations are needed to understand the exact role of BT3
isoforms in a context specific manner.
From previous studies reporting an immunosuppressive role of
BT3 when expressed by immune cells, one could speculate that in
cancer, BT3.2 would favor the tumoral ‘‘immune escape’’ by
decreasing T cell activation. In this context, high expression of
BT3.2 would be related to worse patient prognosis. However, it
was also reported that factors, such as IFN-c and TNF, known to
stimulate the anti-tumoral response, can also up-regulate the
expression of BT3 molecules [12]. The analysis presented here
reveals an interesting profile of BT3.2 by EOC cells (Figure 1 and
Figure 2). We found that almost all EOC cells expressed BT3.2,
but at different levels. A higher expression of BT3.2 by these cells
is strongly associated not only with better patient prognosis, but
also with a higher density of T cells, particularly CD4+ cells. Often
used as markers of T lymphocytes, CD4 and CD8 are generally
associated with T cells despite their low expression being reported
in other cell types. The latter result is in line with recent
observations, where the presence of ovarian tumor-infiltrating T-
cells was associated with a longer patient survival and a longer
progression interval (Table 4). Altogether, these results suggest that
BT3.2 expression by EOC cells may regulate the tumor immune
microenvironment and favor an anti-tumoral immune response.
To confirm this hypothesis, further studies are needed to explore
the co-stimulatory functions of BT3 and their role in regulating the
tumoral immune milieu.
Another interesting observation revealed by this study is the
relation between the TAM and EOC patient prognosis. A few
immunohistochemistry studies have reported a lack of association
between TAM and outcome in ovarian cancer tissues [38,40,44].
However, these studies did not distinguish between polarized M1
or M2 macrophages, since general antibodies against CD68 or
CD36 were used. M1 macrophages, also named classically
activated macrophages, are potent effectors of Th1 responses
and producers of pro-inflammatory cytokines. They are thought to
participate in the immune tumor resistance [45]. In contrast, M2
macrophages, also known as alternative macrophages, have a
crucial role to limit the anti-tumoral immune response and are
thought to foster immune tolerance. M1 and M2 macrophages are
distinguishable by the distinct cytokines and membrane receptors
they express. CD206 is generally highly expressed by M2 polarized
macrophages and considerably less by M1 macrophages, so it is
commonly used to identified M2 macrophages [32,45]. Despite
the lack of association between the density of CD206+ cells and
Table 4. Pearson correlation test (two-tailed) between BT3.2 expression and markers of intra-epithelial immune infiltrate in EOC
tissues.
CD8 CD4 CD20 CD68 CD206 CD206/CD68 BT3.2
CD3 C 0.663 0.657 0.309 0.555 0.436 20.216 0.174
p 0 0 0 0 0 0.005 0.018
N 180 163 182 180 175 170 185
CD8 C 1 0.569 0.468 0.616 0.381 20.161 0.176
p . 0 0 0 0 0.038 0.018
N 181 159 178 175 171 166 180
CD4 C 0.569 1 0.29 0.56 0.495 20.194 0.272
p 0 . 0 0 0 0.013 0
N 159 175 169 169 167 163 175
CD20 C 0.468 0.29 1 0.364 0.171 20.141 0.108
p 0 0 . 0 0.022 0.063 0.137
N 178 169 192 185 179 174 191
CD68 C 0.616 0.56 0.364 1 0.468 20.315 0.059
p 0 0 0 . 0 0 0.42
N 175 169 185 192 180 180 191
CD206 C 0.052 0.13 20.068 0.381 0.495 0.171 0.128
p 0.486 0.077 0.362 0 0 0.022 0.083
N 181 185 183 171 167 179 184
CD206/CD68 C 20.161 20.194 20.141 20.315 0.173 1 20.007
p 0.038 0.013 0.063 0 0.02 . 0.353
N 166 163 174 180 180 180 170
Table showing the Pearson coefficient of correlation C between staining observed for each marker in the intra-epithelial ovarian tumor tissues. Grade and stage were
evaluated according to the FIGO classification. P is the p value from Pearson correlation test. N is the number of cases included in the statistical analysis for which the
observed staining was reliable. CD206/CD68= ratio of CD206+/CD68+ staining in the intra-epithelial area of tumor. C= Pearson correlation coefficient. P=p value.
doi:10.1371/journal.pone.0038541.t004
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proportion of CD206+ cells relative to the total amount of TAM
(CD68+) was strongly associated with early disease progression
(Figure 4C-D). This is in line with previous reports showing that in
vitro M2 tumor macrophages were poorly cytotoxic against
neoplasic cells and produced growth factors for cancer cells [46].
Only a few studies have described the phenotype of TAM in
ovarian cancer tissues. As we observed in our study, the majority of
TAM in cancerous tissues is a M2 CD206+ population
[32,33,47,48,49]. Here, we show for the first time that the relative
density of intraepithelial CD206+/CD68+ cells reflecting M2
TAM, more than the overall quantity of TAM, is a critical factor
associated with a shorter progression-free interval. However, this
observation needs to be validated in an independent cohort.
In summary, we confirmed that BTN3A2/BT3.2 is a new
promising prognostic marker for patients with high grade serous
EOC. As for most biomarkers, it will need to be validated in an
independent cohort of patients to confirm its clinical utility. Even if
Figure 4. Representative staining for immunohistochemistry of infiltrating macrophages. High and low density of CD68+ (tumor-
associated macrophages, TAM) (A) and CD206+ (M2 subtype of TAM) cells (B). Magnification in the high infiltration area is shown on the right panel
for each staining (top). C and D. Kaplan-Meier analysis of the ratio of infiltrating intraepithelial CD206+/CD68+ cells representing the relative density
of CD206+ M2 TAM over the total density of CD68+ intraepithelial infiltrating macrophages. Kaplan-Meier curves of overall survival (C) and disease-
free survival (D) in 180 and 174 patients, respectively. Significance (p) is indicated by log rank.
doi:10.1371/journal.pone.0038541.g004
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data suggest that epithelial expression of BT3.2 is associated with a
beneficial infiltration of immune cells, particularly CD4+ T cells.
This has an important implication for understanding the biology
of these BT3 molecules in the regulation of the anti-tumoral
immune response and EOC patient management after surgery.
Further ‘‘in vitro’’ and ‘‘in vivo’’ experiments need to be done to
better understand the mechanism involved in the immune
regulation by epithelial BT3 in cancer.
Supporting Information
Figure S1 Expression of CD206+ cells by CD68+ mac-
rophages. Representative image. Blue DAPI signal in nuclei.
Image 20X. A. Macrophage CD68+ staining (red). B. CD206+
staining (green). C. Merge staining showing the colocalisation of
CD68 and CD206 markers (orange). CD206 expression is almost
exclusively co-localizing with CD68 staining.
(TIF)
Figure S2 Expression of BT3.2 by other epithelial
cancers. Strong to moderate staining of BT3.2 observed in
colon, renal and breast cancer tissues. Weak staining observed in
prostate cancer tissue.
(TIF)
Table S1 Primary antibodies and conditions used for
immunohistochemistry on tissue microarray.
(DOCX)
Table S2 Kaplan-Meier analysis of immune infiltrate in
199 EOC patients. NA: Not applicable when p value .0.05.
Mean in months from the first resection of the ovarian tumor until
an event of recurrence (disease free survival) or death (overall
survival). Bold indicates significant p values,0.05.
(DOCX)
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